Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia
Posted inCardiology Internal Medicine news

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomagnesemic patients may increase risks, highlighting the necessity of baseline-guided clinical intervention.
Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS
Posted inCardiology Internal Medicine news

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.
Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）
Posted inCardiology Diabetes & Endocrinology news

Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）

A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessity for long-term obesity management.
Superior Durability of Dedicated Balloon-Expandable Bridging Stents in BEVAR: Insights from the BeGraft Peripheral Plus Study
Posted inCardiology General Surgery news

Superior Durability of Dedicated Balloon-Expandable Bridging Stents in BEVAR: Insights from the BeGraft Peripheral Plus Study

A large-scale multicenter study confirms that the BeGraft Peripheral Plus (BGP+) bridging stent graft offers exceptional technical success and high two-year patency rates in branched endovascular aortic repair (BEVAR), establishing it as a reliable dedicated solution for complex aortic aneurysms.
Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock
Posted inCardiology Critical Care news

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock

Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outcomes are heavily influenced by age and treatment delays.
Oxidized Phospholipids on ApoB-100: Dissecting the Link Between Lipoprotein(a), Platelet Reactivity, and Long-Term Cardiovascular Risk
Posted inCardiology news

Oxidized Phospholipids on ApoB-100: Dissecting the Link Between Lipoprotein(a), Platelet Reactivity, and Long-Term Cardiovascular Risk

This evidence-based analysis of the EXCELSIOR trial explores the relationship between OxPL-apoB, platelet activation, and long-term outcomes, finding that while these phospholipids predict major cardiovascular events, they do not appear to mediate their risk through direct platelet reactivity pathways.
Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
Posted inCardiology Nephrology news Transplantation

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP1RAs to mitigate these chronic complications in the post-transplant population.